Eurofins subsidiary empowerDx today launched its PFAS Exposure direct-to-consumer at-home test in the U.S.
Luxembourg-based Eurofins touts the per- and polyfluorinated alkyl substances (PFAS) test as the first direct-to-consumer, at-home test for determining the levels of PFAS in a person’s blood and measure 47 of the PFAS “forever chemical” compounds.
According to a news release, the CDC reports that exposure to such forever chemicals can cause adverse health effects, including cancer, thyroid disease, immune suppression, elevated cholesterol, respiratory disease and decreased fertility.
Eurofins’ PFAS Exposure test, developed by Eurofins Environment Testing companies and their research partners, is a self-administered sampling kit. It uses a simple finger prick rather than the blood draw process that has been required to date, the company said.
The kits offer an all-in-one solution with essentials for collection and transport, allowing for the self-collection of samples at home or work before submitting them directly to a laboratory.